S&P Futures
3,900.50 -3.25 (-0.08%) Dow Futures
31,412.00 -9.00 (-0.03%) Nasdaq Futures
12,023.25 -17.25 (-0.14%) Russell 2000 Futures
1,770.70 +0.90 (+0.05%) Crude Oil
110.78 +1.21 (+1.10%) Gold
1,827.60 +2.80 (+0.15%)
Karolinska Development AB (publ) (0P3C.L)
Chart Events
Performance Outlook
| Previous Close | 2.63 |
| Open | 2.62 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 2.62 - 2.62 |
| 52 Week Range | 2.62 - 2.62 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 7.30 |
| EPS (TTM) | 0.89 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 0P3C.L
Related Research
- GlobeNewswire
Karolinska Development’s portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference
STOCKHOLM, Sweden, June 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Svenska Vaccinfabriken has presented results from a preclinical study indicating that the company’s candidate therapeutic vaccine SVF-001 has potential to elicit an immune response in a disease model of chronic hepatitis B. The results were presented on June 25 at the EASL International Liver CongressTM 2022. Svenska Vaccinfabriken develops therapeutic proteins and DNA vaccin
- GlobeNewswire
Karolinska Development’s portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants
STOCKHOLM, Sweden, June 23, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic today presented preclinical results tshowing that the company’s HAnano Surface coating technology reduces the risk of adhesion by common pathogenic bacteria by up to 60%. Promimic develops and markets HAnano Surface, a unique, nanometer-thin surface treatment that aims to improve the anchorage and healing of orthopedic and dental implants into bone tissue. The techno
- GlobeNewswire
Karolinska Development invests in breakthrough drug project for the treatment of nerve pain
STOCKHOLM, SWEDEN, June 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the company has agreed to invest SEK 20 million in PharmNovo AB, which is developing a novel drug for nerve pain, a difficult-to-treat form of pain that often develops into a chronic condition. The drug candidate PN6047 from PharmNovo has shown compelling efficacy in well-established preclinical disease models, and a first clinical trial is planned to start in late 2022. The estimated market value
